<DOC>
	<DOCNO>NCT02732418</DOCNO>
	<brief_summary>This randomize , partially-blinded , multi-center , parallel-group study evaluate compare PD PK MPA single SC injection either 45 mg/0.3 mL , 75 mg/0.5 mL 105 mg/0.7 mL Depo-Provera CI , one cycle Depo-subQ 104 use injected abdomen , woman reproductive age confirm ovulatory baseline cycle</brief_summary>
	<brief_title>Lower Dose Depo Provera® Contraceptive Injection</brief_title>
	<detailed_description>This randomize , partially-blinded , multi-center , parallel-group study evaluate compare PD PK MPA single SC injection either 45 mg/0.3 mL , 75 mg/0.5 mL 105 mg/0.7 mL Depo-Provera CI , one cycle Depo-subQ 104 use injected abdomen , woman reproductive age confirm ovulatory baseline cycle . Baseline ovulation confirm woman measure serum progesterone ( P ) approximately twice week 2-3 week precede expected menses . Between 48 60 participant ( 12-15 per group ) confirm ovulation meet eligibility criterion enrol randomized receive single SC injection abdomen 1 3 dos Depo-Provera CI : 45 mg/0.3 mL , 75 mg/0.5 mL 105 mg/0.7 mL single dose Depo-subQ Provera ( 104 mg/0.65mL ) . Participants follow 32 week ( 7.5 month ) injection During study participant provide blood sample MPA , P estradiol ( E2 ) prior injection frequently predefined time point 7.5 month . In addition , accurate ascertainment PD response perform transvaginal ultrasound ( TVS ) assess cervical mucus predefined time point 7.5 month . Information adverse event concomitant medication collect throughout study . Information acceptability collect predefined time point 7.5 month .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>typical menstrual cycle 24 35 day confirm ovulatory cycle pretreatment phase ( serum progesterone ≥ 4.7 ng/mL 2 consecutive sample ) sterilize use non hormonal intrauterine device ( IUD ) good general health determine medical history physical examination 18 40 year age ( inclusive ) willing provide inform consent follow study requirement negative urine pregnancy test desire become pregnant subsequent 12 month body mass index ( BMI ) 18.0 35.0 kg/m2 , inclusive hemoglobin ≥10.5 g/L medical contraindication depot medroxyprogesterone acetate ( DMPA ) [ 16 ] undiagnosed mass breast use DMPA past 12 month use combine injectable contraceptive past 6 month use follow medication within 1 month prior enrollment : investigational drug prohibit drug per protocol oral contraceptive Nuvaring contraceptive patch levonorgestrel intrauterine system ( LNG IUS ) contraceptive implant pregnant within last 3 month Is currently lactate use plan use prohibit drug per protocol next 9 month know sensitivity MPA plan move another location next 9 month condition ( social medical ) , opinion investigator would make study participation unsafe , would interfere adherence clinical study requirement complicate data interpretation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CI-contraceptive injection</keyword>
	<keyword>DMPA-Depot medroxyprogesterone acetate</keyword>
	<keyword>MPA-Medroxyprogesterone Acetate</keyword>
	<keyword>subQ-subcutaneous</keyword>
</DOC>